- Trial phase
- Preclinical (Phase 1 for respiratory indications in planning)
- Time to market
- Unknown, a Phase 1 trial is only planned for 2026; if the combination succeeds through trials, any approval would likely be 5+ years away.
- Why 2/10
- APG273 is preclinical with only a Phase 1 trial for asthma/COPD planned in 2026, there is no hard, dated binary (PDUFA or pivotal readout) for this drug itself in the next ~12 months, and the only near-term dated event (the AbbVie $135.11/share cash merger close, expected Q3 2026) is a transaction, not a drug catalyst, and is largely priced into APGE at ~$134.
If you hold APGE, treat it as merger arbitrage: the stock (~$134.16) trades just below the $135.11/share all-cash offer, with close expected Q3 2026 pending shareholder approval. If you invest in ABBV, APG273 is a long-dated pipeline option, watch for Phase 1 initiation in asthma/COPD (planned 2026) and the merger close, but do not buy ABBV for APG273 alone; AbbVie itself ascribes it "modest value" at this early stage.
Price Chart
Executive Summary
APG273 is an early-stage, dual-mechanism asthma/COPD candidate from Apogee Therapeutics (APGE), a co-formulation of its lead antibody zumilokibart (APG777, anti-IL-13) plus APG333 (anti-TSLP). It is preclinical: a Phase 1 respiratory trial is planned for 2026, supported by positive Phase 1 data on the APG333 component. On June 22, 2026, AbbVie agreed to acquire Apogee for $135.11/share in cash (~$10.9B equity value, ~49% premium), with closing expected Q3 2026; AbbVie's own investor deck says it ascribes "modest value" to APG273 given its early stage, with the deal's value centered on zumilokibart. The stock is now a thin merger-arbitrage situation, and APG273's upside/downside will accrue to AbbVie after close.
How It Works
APG273 is a combination (co-formulation) of two engineered antibodies: zumilokibart (APG777), which blocks the inflammatory signal IL-13, and APG333, which blocks TSLP, two proteins that drive asthma and COPD. By blocking both pathways at once, Apogee aims to treat both central and local drivers of airway disease and beat the effectiveness ceiling of single-target drugs, with long-acting antibodies designed to allow dosing only every quarter or twice a year.
Trial Status
No APG273 clinical trial has started. The Phase 1 trial for respiratory indications is in the planning stage (AdisInsight, updated 25 May 2026). Its components have human data: APG333 Phase 1 in healthy volunteers (Nov 2025) showed a long half-life and suppression of type-2 inflammatory markers for up to six months, and preclinical combo data (APG777 + APG333) were presented at ATS 2025.
The Two-Sided Case
Upcoming Catalysts
- AbbVie–Apogee merger close, expected Q3 2026 (subject to Apogee shareholder approval and regulatory conditions), the key dated event for APGE stock.
- APG273 Phase 1 trial initiation in asthma/COPD, planned for 2026 (AdisInsight planning-stage trial), first human data for the combination.
- Zumilokibart context within the same deal: Phase 2 APEX atopic-dermatitis primary completion estimated Nov 2026 and Phase 3 AD start in 2H 2026 (per GlobeNewswire May 27, 2026).
- Disclosure of APG273 respiratory development plans in 2026 (per Synapse pipeline note).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report